← Back to Clinical Trials
Recruiting NCT06973980

HIIT in Sedentary Obese Adults: Effects on Metabolic Risk, Body Composition, and FABP4

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition High-Intensity Interval Training
Sponsor Eastern Mediterranean University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 28
Sex ALL
Min Age 20 Years
Max Age 35 Years
Start Date 2025-03-01
Completion 2025-07-01
Interventions
Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

It is aimed to investigate the responses of Fatty Acid Binding Protein 4 (FABP4), which has been discovered as a novel biomarker of obesity and metabolic diseases, to regular exercise training. The aim of this study is to investigate the effects of high-intensity interval training (HIIT) on cardiometabolic risk factors, body composition, and plasma FABP4 levels in sedentary obese adults.

Eligibility Criteria

Inclusion Criteria: * Aged between 20 and 35 years, * BMI between 30 and 35 kg/m², * Waist circumference of 90-100 cm for women, 105-110 cm for men, * Sedentary lifestyle (\<600 MET-min/week), * Referred by a physician (with a statement confirming no contraindication to exercise)." Exclusion Criteria: * BMI \> 35, * Pregnancy, * Cardiovascular Diseases: Individuals with serious cardiovascular issues, such as uncontrolled hypertension, heart failure, coronary artery disease, or a heart attack within the last 6 months, which could pose a risk during exercise. * Respiratory Diseases: Individuals with chronic respiratory conditions, such as uncontrolled or severe asthma or COPD, who cannot tolerate exercise due to their condition. * Neurological Disorders: Individuals with neurological issues that limit exercise capacity, such as Parkinson's disease, stroke, or multiple sclerosis. * Musculoskeletal Issues: Individuals with chronic musculoskeletal problems, particularly knee or hip osteoart

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}